Colorectal Cancer Treatment
Colorectal Cancer Treatment
Two questions shape colorectal cancer treatment more than any other: whether the operation can preserve the sphincter, and whether the disease outside the bowel can be cleared completely. Both are answered by imaging and molecular testing, not by assumption.
Treatment by stage: sequence before inventory
What separates one colorectal plan from another is usually the order of treatments rather than which treatments exist. The table below sets out the usual sequence; each row carries exceptions decided by the MRI findings and the molecular profile.
| Stage | Usual sequence | What decides the details |
|---|---|---|
| 0 · carcinoma in situ | Endoscopic removal where the lesion can be cleared completely, otherwise segmental surgery | Depth of invasion, completeness of endoscopic removal, and whether the lesion is in the colon or the rectum |
| I | Surgery alone | Depth of invasion; whether the tumour is at high risk of recurrence |
| II | Surgery, with chemotherapy considered only where risk features are present | MSI status, the number of nodes examined, perineural or lymphovascular invasion, obstruction or perforation at presentation |
| III | Surgery followed by chemotherapy; for rectal cancer, treatment before surgery in most cases | Nodal involvement and MRI findings for rectal tumours; the molecular profile for the choice of regimen |
| IV · limited liver deposits | Systemic therapy with planned local treatment of the liver — resection, ablation or arterial therapy | Number, size and distribution of deposits; whether disease outside the liver can also be cleared |
| IV · widespread disease | Systemic therapy in successive lines, guided by re-testing at progression | The molecular profile at progression, symptoms, and which organs are involved |
Surgery: complete excision with nerve preservation
The operation has two simultaneous objectives: removing the tumour with an adequate margin and its lymph node basin, and preserving the nerves that control bowel, urinary and sexual function.
The precision the pelvis requires
"The tumour is low. Will I lose control of my bowel, or need a permanent stoma?"
For rectal cancer, total mesorectal excision removes the rectum together with the fatty envelope containing its lymph nodes, dissecting along an anatomically defined plane. Our surgeons perform this with the robotic platform, whose 10× magnified three-dimensional vision and tremor-free wristed instruments allow that plane to be followed accurately inside a narrow pelvis while the autonomic nerves are identified and preserved. For colon cancer, complete mesocolic excision applies the same principle — dissecting along the embryological plane and taking the central lymph nodes with the vessel. Both reduce the risk of a positive margin and of the functional consequences that follow nerve injury.
Where an operation is not the first step
"The tumour is blocking my bowel. Does that mean emergency surgery and a stoma?"
Not necessarily. Where an obstructing tumour is found, a self-expanding metal stent can be placed through the colonoscope to reopen the passage without an operation. That buys time for full staging, for the patient's condition to be optimised, and for a planned operation to be performed instead of an emergency one. Where the tumour is advanced but not obstructing, local treatment is the other route to a more favourable operation.
Keeping the sphincter: three routes to the same goal
For a low rectal tumour, the fear patients express most often is not the cancer but the prospect of a permanent stoma or of surviving with impaired control. There are three distinct ways to make preservation more likely, used alone or in combination.
Robotic dissection in the narrow pelvis allows the tumour to be removed with a margin while the sphincter and its nerve supply are left intact. Even for tumours close to the anal verge, an ultra-low resection with a hand-sewn or stapled anastomosis can preserve continuity in selected patients.
Where the tumour is too close or too bulky for immediate preservation, superselective transarterial infusion through the inferior mesenteric, superior rectal or internal iliac branches delivers drug concentrations 50 to 100 times higher than intravenous chemotherapy directly into the tumour, and drug-eluting embolisation adds sustained local delivery. After one to three sessions many tumours shrink enough that a sphincter-preserving operation becomes possible where a permanent stoma had been proposed.
A stent placed through the colonoscope relieves the obstruction, converting an emergency presentation into a staged one. This is what allows the full assessment — imaging, molecular testing, nutrition and fitness — to be completed before the operation rather than after it.
Liver metastases: treated as a curable problem when they can be
Up to half of patients with colorectal cancer develop liver metastases, and this is the single most consequential fact in the disease — because colorectal liver deposits are among the most treatable metastases in oncology, provided the distribution allows them all to be dealt with.
Ablation for a few small deposits
For one to three small lesions, radiofrequency, microwave or cryoablation destroys the deposit through a needle under image guidance, with millimetre accuracy and without removing healthy liver. Combined with systemic therapy, this can bring patients to a state of no evidence of disease.
Arterial therapy for multiple or larger deposits
TACE, drug-eluting TACE and hepatic arterial infusion chemotherapy deliver treatment directly into the artery feeding the deposits, achieving local concentrations 50 to 100 times intravenous levels while sparing the rest of the liver. At our Guangzhou hospital the interventional team has performed more than 17,000 TACE procedures between 2023 and 2025.
Radiosurgery for deposits that cannot be operated on
Lesions sitting against a major vessel or in a deep segment are difficult to reach surgically and risky to ablate. CyberKnife converges radiation from thousands of angles at 0.1 mm precision, treating them while preserving the surrounding liver function.
These approaches are combined rather than chosen between: systemic therapy to control the disease systemically, and local treatment to clear what can be cleared. Whether an operation to remove all visible disease is realistic is the question the multidisciplinary meeting answers, and it is worth asking directly.
Radiotherapy, and radiosurgery for recurrence
Radiotherapy has two distinct roles in colorectal cancer: as part of the curative treatment of rectal cancer, where it reduces the risk of local recurrence in the pelvis and is often given before surgery to shrink the tumour, and as a local treatment for recurrences that cannot be operated on. Standard courses run over several weeks; shorter schedules are used in defined situations.
When the cancer returns in one place: radiosurgery instead of re-operation
"There is a new spot at the join, in a pelvic node, or in my lung. Do I need another major operation?"
Often not. CyberKnife M6 stereotactic radiosurgery delivers 0.1 mm precision with real-time tracking, converging beams from thousands of angles onto the target. Postoperative pelvic or anastomotic recurrences, regional lymph node relapses and isolated bone or lung deposits can be ablated in one to five outpatient sessions — without an incision, without adhesions, and without interrupting the systemic treatment already underway. Repeat abdominal surgery carries real morbidity in a pelvis that has already been operated on, and many patients are not candidates for it; radiosurgery avoids that question entirely. Our hospitals have performed more than 1,000 CyberKnife treatments.
Drug treatment: sequenced by molecular profile
Metastatic colorectal cancer requires successive lines of treatment, and which line works depends on what the tumour carries. The table below matches drug groups to molecular findings rather than to the order in which they are conventionally listed.
| Molecular finding | Drug groups used |
|---|---|
| MSI-H or mismatch repair deficient | PD-1 immunotherapy, approved as first-line standard of care in China rather than reserved for later lines |
| RAS wild-type, left-sided tumour | Anti-EGFR monoclonal antibodies combined with chemotherapy, sequenced appropriately |
| BRAF V600E | Combined BRAF and EGFR inhibition, which outperforms standard chemotherapy in this group |
| HER2 amplified | Anti-HER2 antibody combinations, including antibody-drug conjugates in previously treated disease |
| KRAS G12C | Specific KRAS G12C inhibitors, already approved in China |
| After standard lines are exhausted | Anti-angiogenic agents combined with immunotherapy, and phase III clinical trials of agents typically three to five years ahead of availability elsewhere |
Finishing the course: managing what interrupts treatment
Colorectal cancer treatment extends over months, and the commonest reason a patient cannot complete it is the accumulation of side effects rather than the disease itself. Two are specific to this cancer.
Neuropathy and bowel dysfunction
Oxaliplatin causes a cold-sensitive neuropathy that can become persistent and is a frequent reason for stopping or reducing treatment. Postoperative bowel dysfunction — frequency, urgency and irregularity after a low resection — affects quality of life for months and is sometimes assumed to be untreatable. Integrative protocols combining herbal formulations and acupuncture are directed at both, alongside physical measures and dietary adjustment.
Stoma adaptation and recovery
Where a stoma is needed, whether temporary or permanent, specialist stoma care is part of the plan rather than a separate concern: appliance selection, skin management, and practical training before discharge. Patients who are prepared for a stoma manage it far better than those who are handed one on the ward, and this is a service we treat as part of the operation.
Integrative treatment is given as support alongside standard oncology treatment, supervised by clinicians who know what the patient is receiving.
A single recommendation, delivered in 48 hours
Why colorectal cancer is decided in a meeting
Colorectal cancer decisions cross departmental boundaries more than most: whether the sphincter can be preserved is a surgical and radiological question, whether liver deposits can be cleared is a hepatobiliary and interventional one, and which drug comes first is a molecular one. Colorectal surgery, hepatobiliary surgery, interventional radiology, medical oncology, radiation oncology, radiology and pathology review each case together and issue one written plan. Send your records and receive that plan within 48 hours of the file being complete — whether you intend to travel or want a second opinion to use at home.
If you are establishing what you have rather than what to do about it, begin with how colorectal cancer is diagnosed. The risk factors behind the disease and how they can be modified are covered in causes and risk factors and prevention and screening.